REVEAL Study Patient Eligibility Criteria

A wide range of patients with PV may be eligible for the REVEAL study.

Key Inclusion Criteria	Key Exclusion Criteria
Age ≥18 years Diagnosis of PV Willing and able to provide signed informed consent Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Under the supervision of a physician for the active management of PV, including but not limited to watchful waiting, ASA 81 mg or greater, antithrombotic therapy, PHL, HU, interferon (recombinant or pegylated busulfan), anagrelide	Participation in an active clinical trial in which the study treatment is blinded Life expectancy <6 months Diagnosis of myelofibrosis (MF) (including primary MF or post-PV MF or post-essential thrombocythemia [ET] MF) Diagnosis of acute myelocytic leukemia (AML) Diagnosis of Myelodysplastic Syndrome History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months Splenectomy

Key Inclusion Criteria

Key Exclusion Criteria

Age ≥18 years
Diagnosis of PV
Willing and able to provide signed informed consent
Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
Under the supervision of a physician for the active management of PV, including but not limited to watchful waiting, ASA 81 mg or greater, antithrombotic therapy, PHL, HU, interferon (recombinant or pegylated busulfan), anagrelide

Participation in an active clinical trial in which the study treatment is blinded
Life expectancy <6 months
Diagnosis of myelofibrosis (MF) (including primary MF or post-PV MF or post-essential thrombocythemia [ET] MF)
Diagnosis of acute myelocytic leukemia (AML)
Diagnosis of Myelodysplastic Syndrome
History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
Splenectomy